hotspot -WSS

hotspot

author：knowledge 2025-10-01 04:12:20 - browse：613

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Arc Institute generative AI designs new CRISPR systems

WSS

'Investigate these claims': UFO transparency at center of House hearing

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Second House panel advances two

Glen Campbell's doctor discusses his public struggle with Alzheimer's

STAT Report: Patient voices and perspectives

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Wikipedia

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Cancer drug shortages should be causing more outrage

Biogen says it will cut costs by $700 million, slash 1,000 jobs

State Dept. review finds Biden bears some blame for Afghanistan failures

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Virginia high school admissions case could be legal follow

HIV vaccine remains elusive. Immunologists keep trying new ideas

Walensky prepares to leave CDC — and Congress — behind

The haunting brain science of long Covid

Wikipedia

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Case highlights the risks of experimental stem cell therapy

Glen Campbell's doctor discusses his public struggle with Alzheimer's

NVIDIA and Google execs on the future of AI and drug discovery

Dems pitch expanding Medicare power to negotiate drug prices

Device maker Teleflex to acquire urology company for $600M

leisure time

knowledge

focus

explore